The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...

Poynter has partnered with the Risk Less. Do More. campaign to host a webinar, articles to better inform journalists.

Enanta Pharmaceuticals' EDP-323 shows promising Phase 2a trial results, significantly reducing RSV viral load and symptoms ...

The Temperature-Activated Generation of Signal (TAGS) technology was developed by Roche for its high-throughput PCR-based instruments.

As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics has announced the launch of its advanced ...

The COVID-19 pandemic made the public acutely aware of how vulnerable their noses are. | The COVID-19 pandemic made us ...

Vicebio has secured $100mn in Series B funding to further develop its vaccines for multiple respiratory infections.

A possible cluster of bird flu infections has grown to include eight people, in what may be the first examples of ...

As the 2024-2025 respiratory virus season gets under way, statewide infectious disease experts urge everyone in Oregon to ...

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With RSV ...

Respiratory syncytial virus (RSV ... Key exclusion criteria were positivity for the human immunodeficiency virus, concurrent influenza virus infection or bacterial pneumonia, and known or ...

The complex shape of respiratory syncytial virus (RSV) is one hurdle limiting the development of treatments for an infection ...